Anti-PD-L1 monoclonal antibody therapy is clinically approved for several types of cancer [59,60], and may combine effectively with the PD-L1 upregulation on MYCN-non-amplified neuroblastoma cells resulting from PBNP-PTT treatment (Figure 5A). Here, CD274 is linked to neuroblastoma.